In melanoma researches, TIDE was identified to be more accurate than other markers, including mutant load and PD‐L1 expression, in the prognosis of first‐line anti‐CTLA4 and/or anti‐PD1 antibody treatment.16 This evidence concerns the gene CTLA4 and melanoma.